Early safety check: psoriasis pill tested in people with liver issues
NCT ID NCT06376474
Summary
This early-stage study aims to understand how a potential psoriasis drug, Hemay005, is processed by the body in people with mild or moderate liver impairment compared to those with normal liver function. It involves 24 participants who will take a single dose. The main goal is to gather safety data to help determine appropriate doses for future patients whose livers may not work normally.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital of Tongji Medical College; Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.